Teachers Retirement System of The State of Kentucky Sells 15,249 Shares of Glaukos Corporation $GKOS

Key Points

• Teachers Retirement System of Kentucky cut its Glaukos stake by 52.0% in Q4, selling 15,249 shares and leaving 14,051 shares valued at about $1.59 million.
• Insiders have been net sellers, unloading 19,657 shares worth roughly $2.25 million over the past 90 days (including sales by the CFO and a director); insiders now own about 6.4% of the company.
• Analysts give Glaukos a consensus rating of “Moderate Buy” with an average target of $133.69; the company recently missed EPS estimates (-$0.28 vs. -$0.22) while reporting revenue up 35.6% to $143.12 million.

Teachers Retirement System of The State of Kentucky cut its position in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 52.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,051 shares of the medical instruments supplier's stock after selling 15,249 shares during the quarter. Teachers Retirement System of The State of Kentucky's holdings in Glaukos were worth $1,586,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in GKOS. First Horizon Corp raised its stake in Glaukos by 1,715.4% during the fourth quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier's stock valued at $27,000 after buying an additional 223 shares during the last quarter. UMB Bank n.a. raised its stake in Glaukos by 102.6% during the third quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier's stock valued at $25,000 after buying an additional 158 shares during the last quarter. Farther Finance Advisors LLC raised its stake in Glaukos by 111.4% during the fourth quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier's stock valued at $46,000 after buying an additional 215 shares during the last quarter. Salomon & Ludwin LLC raised its stake in Glaukos by 111.2% during the fourth quarter. Salomon & Ludwin LLC now owns 454 shares of the medical instruments supplier's stock valued at $51,000 after buying an additional 239 shares during the last quarter. Finally, REAP Financial Group LLC purchased a new position in Glaukos during the third quarter valued at $40,000. 99.04% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on GKOS shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Glaukos in a research note on Tuesday, April 21st. Wall Street Zen cut Glaukos from a "buy" rating to a "hold" rating in a research report on Saturday, February 21st. Needham & Company LLC upped their price objective on Glaukos from $125.00 to $127.00 and gave the company a "buy" rating in a research report on Wednesday, February 18th. Wells Fargo & Company upped their price objective on Glaukos from $122.00 to $135.00 and gave the company an "overweight" rating in a research report on Wednesday, February 18th. Finally, Stephens upped their price objective on Glaukos from $115.00 to $145.00 and gave the company an "overweight" rating in a research report on Friday, January 2nd. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $133.69.

Glaukos Stock Performance

Shares of GKOS opened at $119.71 on Wednesday. The company has a quick ratio of 4.06, a current ratio of 4.69 and a debt-to-equity ratio of 0.10. The business has a 50-day simple moving average of $113.59 and a two-hundred day simple moving average of $107.37. The stock has a market cap of $7.01 billion, a price-to-earnings ratio of -36.72 and a beta of 0.78. Glaukos Corporation has a 52 week low of $73.16 and a 52 week high of $130.23.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings data on Tuesday, February 17th. The medical instruments supplier reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.06). Glaukos had a negative return on equity of 7.00% and a negative net margin of 36.99%.The company had revenue of $143.12 million during the quarter, compared to the consensus estimate of $132.16 million. During the same period last year, the business earned ($0.40) EPS. The firm's quarterly revenue was up 35.6% compared to the same quarter last year. On average, analysts expect that Glaukos Corporation will post -0.57 EPS for the current year.

Insider Transactions at Glaukos

In other news, CFO Alex R. Thurman sold 2,511 shares of Glaukos stock in a transaction dated Wednesday, March 25th. The stock was sold at an average price of $106.46, for a total transaction of $267,321.06. Following the transaction, the chief financial officer directly owned 41,967 shares of the company's stock, valued at $4,467,806.82. The trade was a 5.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Aimee S. Weisner sold 15,000 shares of Glaukos stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $117.38, for a total value of $1,760,700.00. Following the transaction, the director directly owned 18,806 shares in the company, valued at approximately $2,207,448.28. The trade was a 44.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 19,657 shares of company stock worth $2,250,060. Insiders own 6.40% of the company's stock.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.